샘플 요청 목록

 카트 문의
시장보고서
상품코드
1758980

세계의 맞춤형 의료 분야 생성형 AI 시장

Generative Artificial Intelligence (AI) in Personalized Medicine
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 140 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

맞춤형 의료 분야 생성형 AI 세계 시장은 2030년까지 9억 1,920만 달러에 이를 전망

2024년에 2억 5,920만 달러로 추정된 맞춤형 의료 분야 생성형 AI 세계 시장은 2030년에는 9억 1,920만 달러에 이르고, 분석 기간인 2024-2030년 CAGR은 23.5%를 보일 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 On-Premise 전개는 CAGR 21.0%를 나타내고, 분석 기간 종료시에는 5억 6,500만 달러에 이를 것으로 예측됩니다. 클라우드 기반 전개 부문의 성장률은 분석 기간중 CAGR 28.2%로 추정됩니다.

미국 시장은 6,810만 달러로 추정, 중국은 CAGR 22.4%로 성장 예측

미국의 맞춤형 의료 분야 생성형 AI 시장은 2024년에 6,810만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 22.4%로 성장을 지속하여, 2030년에는 1억 4,100만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 21.1%와 20.5%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 16.4%를 보일 전망입니다.

세계 '맞춤형 의료 분야 생성형 AI(생성형 AI)' 시장 - 주요 동향 및 촉진요인 정리

생성형 AI와 맞춤형 의료의 융합이 탄력을 받는 이유는 무엇일까?

제너레이티브 인공지능(AI)을 맞춤형 의료에 통합하는 것은 헬스케어 패러다임의 변화를 상징하며, 컴퓨팅 혁신, 유전체 과학, 환자 중심 치료 모델의 융합을 통해 빠르게 추진되고 있습니다. 생성형 AI는 합성 바이오마커 프로파일, 치료 시뮬레이션, 약물 분자 구조 등 새로운 데이터 출력을 생성할 수 있는 모델을 포함하며, 의료 개입을 개인에 맞게 조정하는 데 중요한 역할을 하고 있습니다. 이러한 추세는 유전체 시퀀싱, 전자 의료 기록(EHR), 이미지 파일, 환자의 라이프스타일 데이터 등 다차원적인 헬스케어 데이터의 급격한 증가에 의해 촉진되고 있습니다. 그 결과, AI 시스템은 전례 없는 정확도로 질병의 진행과 치료 결과를 시뮬레이션하는 예측 모델을 생성할 수 있게 되었습니다. 병원과 연구기관은 이러한 기능을 활용하여 진단을 정교화하고, 치료 계획을 개인화하고, 임상 워크플로우를 간소화하는 데 활용하고 있습니다. 의료 서비스 제공을 지원하는 디지털 인프라도 플랫폼 간 상호운용성 향상과 환자 안전을 보장하면서 혁신을 촉진하는 규제 프레임워크에 힘입어 AI 용도에 대응할 수 있도록 진화하고 있습니다. 또한, 북미와 아시아태평양과 같이 데이터가 풍부한 지역에서는 탄탄한 생명공학 생태계와 자금 조달 지원 체계에 힘입어 AI 도입이 급증하고 있습니다. 이러한 요소들이 결합되어 헬스케어 가치사슬이 재편되고 있으며, 생성형 AI가 맞춤형 의료의 진화를 위한 초석으로 자리매김하고 있습니다.

생성형 AI가 신약개발을 어떻게 변화시킬 것인가?

개인화된 의료에서 생성형 AI의 가장 파괴적인 영향 중 하나는 AI가 의약품의 설계, 시험 및 승인 방식을 근본적으로 변화시키고 있는 신약 개발 분야에서 관찰됩니다. 전통적인 신약 개발은 자원 집약적이고 시간이 오래 걸리며, 신약 출시에 10년 이상, 수십억 달러의 투자가 필요한 경우가 많습니다. 생성 모델, 특히 변분 자동 인코더(VAE), 트랜스포머, 확산 모델과 같은 아키텍처에 구축된 모델은 실리콘 내에서 수천 개의 잠재적 화합물을 신속하게 생성하고 평가할 수 있어 연구 개발의 초기 단계를 획기적으로 단축할 수 있습니다. 이러한 모델은 환자별 유전자 변이 및 바이오마커와 일치하는 약물 후보를 식별하는 데 특히 효과적이며, 이는 맞춤형 의료의 기본 원칙에 부합합니다. 또한 AI는 다양한 분자가 인간 단백질과 상호 작용하는 방식을 시뮬레이션하고, 집단별 데이터를 기반으로 부작용 가능성을 예측하여 의약품의 안전성 프로파일을 개선할 수 있습니다. 스타트업과 대형 제약사 모두 AI 우선의 파이프라인을 채택하여 희귀 유전성 질환과 같이 기존 약물 모델이 경제적으로 실행 불가능한 틈새 질환을 타겟으로 삼고 있습니다. 하이테크 기업과 제약사의 파트너십은 이러한 추세를 가속화하는 핵심적인 역할을 하고 있으며, 많은 경우 합작투자와 전용 AI 신약개발 플랫폼이 탄생하고 있습니다. 지적재산권 또한 진화하고 있으며, AI가 만들어낸 화합물은 특허성에 대한 기존의 틀에 도전하고 있습니다. 규제 기관은 AI가 개발한 치료법을 보다 신속하게 검증할 수 있도록 적응성 있는 가이드라인을 마련하고 있습니다. 전반적으로 이러한 기술 변화로 인해 개인 맞춤형 치료제의 개발이 그 어느 때보다 민첩하고, 비용 효율적이며, 정확하게 이루어지고 있습니다.

이 시장 형성에 있어 환자와 의료 서비스 제공업체는 어떤 역할을 할 수 있을까?

맞춤형 의료에서 생성형 AI의 광범위한 채택은 기술적 준비의 기능뿐만 아니라 환자, 의료 제공업체 및 의료 시스템의 행동 변화를 반영합니다. 현대의 환자들은 웨어러블과 모바일 앱을 통해 자신의 건강 데이터에 접근할 수 있게 되면서 맞춤형 케어 솔루션에 대한 수요가 증가하고 있습니다. 이들은 자신의 유전자 및 라이프 스타일 프로파일을 반영한 정밀 치료를 원하는 경향이 강해 AI 기반 진단 및 치료 도구에 대한 비옥한 시장을 창출하고 있습니다. 동시에 의료 서비스 제공업체들은 AI 기반 의사결정 지원 시스템을 통합하여 개인화된 치료 권고안을 생성하고, 치료 결과를 시뮬레이션하며, 개인화된 임상 문서를 작성하는 등 AI를 활용한 의사결정 지원 시스템을 통합하고 있습니다. 이를 통해 의사는 더 많은 정보를 바탕으로 데이터에 기반한 의사결정을 내릴 수 있어 임상 생산성이 향상되고 환자 예후가 개선될 수 있습니다. 시스템 측면에서 병원 및 클리닉은 맞춤형 의료의 성공에 필수적인 실시간 멀티소스 데이터 융합을 가능하게 하는 AI 통합 전자 의료 기록 시스템으로 전환하고 있습니다. 보험사들도 AI를 활용하여 맞춤형 의료 플랜과 예측 리스크 모델을 도입하는 등 적응을 시작하고 있습니다. 한편, 학계는 의료 교육 프로그램에 AI 모듈을 통합하여 미래의 의료 전문가들이 AI 확장 환경에서 활동할 수 있도록 준비하고 있습니다. 개인화된 AI 지원 의료 서비스로의 집단적 전환은 개인화된 위험 평가를 통해 예방적 치료와 만성질환 관리를 촉진하는 공중보건 이니셔티브에 의해 더욱 강화되고 있습니다. 이러한 생태계 전반의 변화는 소비자의 기대와 기술적 역량 간의 일치도가 높아지면서 의료 개인화에서 생성형 AI의 역할을 확고히 하고 있습니다.

맞춤형 의료에서 생성형 AI 세계 시장 수요 급증 요인은?

맞춤형 의료 분야의 생성형 AI 시장의 성장은 기술의 진화, 최종 사용자 확대, 시스템 혁신과 직결되는 몇 가지 요인에 의해 이루어지고 있습니다. 첫째, 유전체학, 전사체학, 단백질체학, 환자 이력 등 대규모의 고해상도 데이터 세트의 가용성으로 인해 생성형 모델에 이상적인 훈련 환경이 구축되어 임상적으로 유의미한 인사이트를 도출할 수 있는 역량이 강화되었습니다. 둘째, 전장 유전체 염기서열 분석과 분자진단의 비용 감소로 인해 사용자층이 크게 확대되어 더 많은 사람들이 맞춤형 의료에 접근할 수 있게 되었습니다. 기술적으로는 클라우드 인프라, 엣지 컴퓨팅, 대규모 언어 모델(LLM) 아키텍처의 급속한 발전으로 방대한 생물의학 데이터 세트를 실시간으로 처리할 수 있게 되었습니다. 종양학, 신경학, 면역학 등의 최종 사용 분야에서는 개인화된 치료 경로로 질병 아형을 타겟팅하고, 임상 효과를 높이고 부작용을 줄이기 위해 생성형 AI를 통합하고 있습니다. 또한, 제약사 및 생명공학 기업들은 파이프라인 개발을 가속화하고 R&D 오버헤드를 줄이기 위해 AI와의 협업에 많은 투자를 하고 있습니다. 임상시험의 최적화도 중요한 원동력이며, AI가 생성한 가상 코호트가 결과 시뮬레이션에 사용되어 대규모 환자 모집에 대한 의존도를 낮추고 있습니다. 특히 미국, 중국, 독일, 한국의 혁신 허브에서는 정부 보조금, 벤처캐피털 동향, 민관 이니셔티브가 이러한 추세를 강화하고 있습니다. 규제 환경 또한 AI 기반 신청에 대응할 수 있도록 진화하고 있으며, 보다 빠른 납기와 시험 설계의 유연성을 제공합니다. 마지막으로, 개인화된 치료 계획에 대한 환자들의 선호도가 높아지면서 AI가 생성하는 결과물에 대한 임상의들의 신뢰와 함께 헬스케어 생태계 전반에 걸쳐 AI를 도입하는 데 박차를 가하고 있습니다. 이러한 시장 성장 촉진요인을 종합하면, 개인화된 의료 분야에서 생성형 AI 용도 세계 시장은 꾸준히 성장하고 있습니다.

부문

전개(On-Premise 전개, 클라우드 기반 전개), 용도(병원＆클리닉, 외래수술센터(ASC), 기타 용도)

조사 대상 기업 예

  • Ada Health
  • Antidote AI
  • BenevolentAI
  • BioSymetrics
  • Berg Health
  • BioAge Labs
  • Blackford Analysis
  • Brightseed
  • CloudMedx
  • Deep Genomics
  • Enara Bio
  • Exscientia
  • GNS Healthcare
  • Helium Health
  • Insilico Medicine
  • IBM Watson Health
  • Kheiron Medical
  • LifeOmic
  • Lunit
  • Medtronic AI

AI 통합

우리는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH

Global Generative Artificial Intelligence (AI) in Personalized Medicine Market to Reach US$919.2 Million by 2030

The global market for Generative Artificial Intelligence (AI) in Personalized Medicine estimated at US$259.2 Million in the year 2024, is expected to reach US$919.2 Million by 2030, growing at a CAGR of 23.5% over the analysis period 2024-2030. On-Premise Deployment, one of the segments analyzed in the report, is expected to record a 21.0% CAGR and reach US$565.0 Million by the end of the analysis period. Growth in the Cloud-based Deployment segment is estimated at 28.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$68.1 Million While China is Forecast to Grow at 22.4% CAGR

The Generative Artificial Intelligence (AI) in Personalized Medicine market in the U.S. is estimated at US$68.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$141.0 Million by the year 2030 trailing a CAGR of 22.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 21.1% and 20.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.4% CAGR.

Global "Generative Artificial Intelligence (AI) in Personalized Medicine" Market - Key Trends & Drivers Summarized

Why Is the Intersection of Generative AI and Personalized Medicine Gaining Momentum?

The integration of generative artificial intelligence (AI) into personalized medicine represents a paradigm shift in healthcare, one that is being rapidly propelled by the convergence of computational innovation, genomic science, and patient-centered care models. Generative AI, which includes models capable of creating novel data outputs-such as synthetic biomarker profiles, treatment simulations, or drug molecule structures-has found a critical role in tailoring medical interventions to the individual level. This trend is being catalyzed by the exponential growth of multi-dimensional healthcare data, including genomic sequencing, electronic health records (EHRs), imaging files, and patient lifestyle data. As a result, AI systems can now generate predictive models that simulate disease progression or treatment outcomes with unprecedented accuracy. Hospitals and research institutions are leveraging these capabilities to refine diagnosis, personalize care plans, and streamline clinical workflows. The digital infrastructure underpinning healthcare delivery is also evolving to accommodate AI applications, supported by increasing interoperability between platforms and regulatory frameworks that promote innovation while ensuring patient safety. Additionally, data-rich regions such as North America and parts of Asia-Pacific are witnessing a surge in AI adoption, driven by their robust biotechnology ecosystems and supportive funding landscapes. Together, these elements are reshaping the healthcare value chain and positioning generative AI as a cornerstone technology in the evolution of personalized medicine.

How Is Drug Discovery Being Transformed by Generative AI?

One of the most disruptive impacts of generative AI in personalized medicine is observed in the drug discovery and development sector, where AI is fundamentally altering how pharmaceutical products are designed, tested, and approved. Traditional drug discovery is resource-intensive and time-consuming, often requiring over a decade and billions in investment to bring a new drug to market. Generative models-especially those built on architectures like variational autoencoders (VAEs), transformers, and diffusion models-can rapidly generate and evaluate thousands of potential compounds in silico, dramatically compressing the early stages of R&D. These models are particularly effective in identifying drug candidates that align with a patient's unique genetic mutations or biomarkers, thereby aligning with the core principles of personalized medicine. Further, AI can simulate how different molecules interact with human proteins or predict the likelihood of side effects based on population-specific data, improving drug safety profiles. Startups and pharma giants alike are adopting AI-first pipelines to target niche conditions, such as rare genetic diseases, where conventional drug models are not economically viable. Partnerships between tech companies and pharmaceutical firms have become central to accelerating this trend, often resulting in joint ventures or dedicated AI drug discovery platforms. Intellectual property is also evolving, as AI-generated compounds challenge existing frameworks for patentability. Regulatory bodies are responding with adaptive guidelines, allowing faster validation of AI-developed therapies. Altogether, this technological shift is making the development of personalized therapeutics more agile, cost-efficient, and precise than ever before.

What Role Do Patients and Healthcare Providers Play in Shaping This Market?

The broader adoption of generative AI in personalized medicine is not only a function of technological readiness but also reflects changing behaviors among patients, providers, and healthcare systems. Modern patients, increasingly empowered by access to their own health data through wearables and mobile apps, are driving demand for customized care solutions. They are more inclined to seek out precision treatments that reflect their unique genetic and lifestyle profiles, creating a fertile market for AI-based diagnostic and therapeutic tools. At the same time, healthcare providers are integrating AI-powered decision support systems that generate individualized treatment recommendations, simulate treatment outcomes, and even produce personalized clinical documentation. This enhances clinical productivity and improves patient outcomes, as physicians can make more informed, data-backed decisions. From a systems perspective, hospitals and clinics are transitioning to AI-integrated electronic health record systems that enable real-time, multi-source data fusion-crucial for the success of personalized medicine. Insurers are also beginning to adapt, using AI to underwrite personalized health plans and predictive risk models. Meanwhile, academic institutions are incorporating AI modules into medical training programs, preparing future healthcare professionals to operate in this AI-augmented environment. The collective shift toward personalized, AI-enabled care delivery is further reinforced by public health initiatives that promote preventive care and chronic disease management through individualized risk assessments. These ecosystem-wide changes indicate a growing alignment between consumer expectations and technological capabilities, solidifying generative AI’s role in the personalization of medicine.

What’s Fueling the Surge in Global Market Demand for Generative AI in Personalized Medicine?

The growth in the generative AI in personalized medicine market is driven by several factors directly tied to technological evolution, end-user expansion, and systemic transformation. First, the availability of large-scale, high-resolution datasets-from genomics, transcriptomics, proteomics, and patient histories-creates the ideal training environment for generative models, enhancing their ability to produce clinically relevant insights. Second, the decreasing cost of whole-genome sequencing and molecular diagnostics has significantly expanded the user base, making personalized care accessible to a broader population. On the technological front, rapid advancements in cloud infrastructure, edge computing, and large language model (LLM) architectures have made it feasible to process vast biomedical datasets in real time. End-use sectors such as oncology, neurology, and immunology are increasingly integrating generative AI to target disease subtypes with personalized treatment pathways, leading to better clinical efficacy and reduced adverse effects. Additionally, pharma and biotech companies are investing heavily in AI collaborations to accelerate pipeline development and reduce R&D overhead. Clinical trial optimization is another critical driver, with AI-generated virtual cohorts being used to simulate outcomes and reduce dependency on large-scale patient recruitment. Government grants, venture capital flows, and public-private initiatives are reinforcing this trend, especially in innovation hubs across the U.S., China, Germany, and South Korea. Regulatory environments are also evolving to accommodate AI-based submissions, offering faster turnaround times and greater flexibility in trial designs. Lastly, growing patient preference for individualized care plans, coupled with clinician trust in AI-generated outputs, is fueling adoption across healthcare ecosystems. Collectively, these drivers point to a robust and expanding global market for generative AI applications in personalized medicine.

SCOPE OF STUDY:

The report analyzes the Generative Artificial Intelligence (AI) in Personalized Medicine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Deployment (On-Premise Deployment, Cloud-based Deployment); Application (Hospitals & Clinics Application, Ambulatory Surgery Centers Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Ada Health
  • Antidote AI
  • BenevolentAI
  • BioSymetrics
  • Berg Health
  • BioAge Labs
  • Blackford Analysis
  • Brightseed
  • CloudMedx
  • Deep Genomics
  • Enara Bio
  • Exscientia
  • GNS Healthcare
  • Helium Health
  • Insilico Medicine
  • IBM Watson Health
  • Kheiron Medical
  • LifeOmic
  • Lunit
  • Medtronic AI

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Generative Artificial Intelligence (AI) in Personalized Medicine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Generative AI Algorithms Drive Precision Treatment Planning and Custom Drug Design
    • Integration of Multi-Omics Data Sets Strengthens Business Case for AI-Enabled Personalization
    • Rising Investment in Digital Health Accelerates Adoption of Generative AI in Clinical Decision Support
    • Partnerships Between Biotech Firms and AI Startups Generate Breakthrough Innovations in Therapy Design
    • Use of AI-Generated Digital Twins Throws Spotlight on Predictive Patient Response Modeling
    • Demand for Real-Time Adaptive Treatment Algorithms Expands Addressable Market for AI Tools
    • Ethical and Regulatory Frameworks Shape Responsible AI Integration in Personalized Medicine
    • Increased Use of Generative AI in Rare Disease Discovery Propels Pharmaceutical Interest
    • Data Privacy and Model Transparency Requirements Drive Investment in Explainable AI Systems
    • Growing Clinical Trial Complexity Sustains AI Adoption in Virtual Patient Recruitment and Simulation
    • Interoperability Between AI Models and EHR Systems Generates Hospital-Level Deployment Opportunities
    • Healthcare Payers Shift Toward Value-Based Care Supports Investment in Outcome-Driven AI Tools
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Generative Artificial Intelligence (AI) in Personalized Medicine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for On-Premise Deployment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for On-Premise Deployment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Cloud-based Deployment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Cloud-based Deployment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals & Clinics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals & Clinics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Ambulatory Surgery Centers Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • CHINA
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • FRANCE
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Rest of Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of World 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of World 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제